DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s disease
Description: PROJECT NARRATIVE Alzheimer’s disease (AD) is the most common form of dementia in the elderly population, affecting more than 5 million Americans and 15 million people worldwide. The development of effective disease-modifying therapeutics for AD would greatly benefit from in vivo biomarkers, preferentially those that tag the very earliest stages of the disease. It is critical to establish a panel of valid biomarkers for diagnosis and monitoring its progression, or even prevent it by targeting several pharmaceutical candidates. Despite several existing biomarkers for AD, they do not capture the heterogeneity of the disease and more importantly, lack the sensitivity and specificity for early diagnosis. To address this key challenge and knowledge gap, this proposal aims to develop an innovative multi-faceted approach enabled by multiplexed protein quantitation technology and new advancements of MS instrumentation coupled with front-end sample enrichment and separation strategies for improved glycoproteomics and PTM crosstalk analysis. These technological advancements in combination with clinical neuroimaging will accelerate novel AD biomarker discovery and validation. The successful outcome of this research will have broad impact on translational medicine and will have profound impact on the physical and emotional health of millinois of individual patients at risk for this devastating diease.
Funder: National Institute on Aging
Funding type: research
Funder scheme: R01
Start date: 2018-01-15
End date: 2028-02-29
Investigator: LINGJUN LI (lead)
Institutions: University of Wisconsin–Madison, UNIVERSITY OF WISCONSIN-MADISON
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Funded outputs count: 103
Funder award ID: R01AG052324
OpenAlex ID: G9000896066
